← All trials
NCT00006479
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2000
- Primary completion
- —
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- CHU AMBROISE PAREOfficial
- CHU AMBROISE PAREStudy chair
- Arbeitsgruppe Lebermetastasen und TumorenStudy chair
- Moorgreen Hospital, SouthamptonStudy chair
- Australasian Gastro-Intestinal Trials GroupCollaborator
- Arbeitsgruppe Lebermetastasen und TumorenCollaborator
- Cancer Research UKCollaborator
- Fondation Francaise de Cancerologie DigestiveCollaborator
- University of SydneyStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.